Last reviewed · How we verify
An Open, Multicenter, Non-Comparative Study To Assess The Efficacy And Tolerability Of Intramuscular Ziprasidone Followed By Oral Ziprasidone In Patients With Acute Psychosis
To assess the efficacy, safety, and tolerability of intramuscular ziprasidone in the treatment of the acute exacerbation of non-organic psychosis of any etiology, including schizophrenia, acute mania, delusional disorder and others.
Details
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 89 |
| Start date | 2003-07 |
| Completion | 2004-05 |
Conditions
- Schizophrenia
- Mania
- Delusional Disorder
- Acute Exacerbation of Psychosis
Interventions
- Ziprasidone
Primary outcomes
- Change from baseline in Positive and Negative Syndrome Scale (PANSS) excitation items scores — Days 1-3 (end of intramuscular dosing)
Countries
Brazil